Lovastatin
- Generic Name
- Lovastatin
- Brand Names
- Advicor, Altoprev
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36O5
- CAS Number
- 75330-75-5
- Unique Ingredient Identifier
- 9LHU78OQFD
- Background
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of Aspergillus terreus. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inh...
- Indication
Lovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C. It is indicated as an intervention alternative in individuals presenting dyslipidemia...
- Associated Conditions
- Apolipoprotein, Cholesterol, LDL, Coronary Artery Atherosclerosis, Coronary Revascularization, Myocardial Infarction, Peripheral Arterial Disease (PAD), Unstable Angina Pectoris, Elevation of serum triglyceride levels, Total cholesterol increased
- Associated Therapies
- -
Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown PrimaryMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell CarcinomaMetastatic Nasopharyngeal Squamous Cell CarcinomaMetastatic Oral Cavity Squamous Cell CarcinomaMetastatic Oropharyngeal Squamous Cell CarcinomaMetastatic Paranasal Sinus Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 28
- Registration Number
- NCT06636734
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Lovastatin for Treatment of Brain Arteriovenous Malformations
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 1244
- Registration Number
- NCT04297033
- Locations
- 🇨🇳
Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 153
- Registration Number
- NCT03510884
- Locations
- 🇪🇸
Investigational Site Number :7240003, Pamplona, Navarra, Spain
🇵🇱Investigational Site Number :6160002, Gdansk, Pomorskie, Poland
🇲🇽Investigational Site Number :4840007, Oaxaca, Mexico
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT03510715
- Locations
- 🇩🇰
Investigational Site Number 2080001, Viborg, Denmark
🇪🇸Investigational Site Number 7240001, A Coruna, Spain
🇸🇮Investigational Site Number 7050001, Ljubljana, Slovenia
Synaptic Plasticity and Cognitive Function in RASopathies
- Conditions
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 16
- Registration Number
- NCT03504501
- Locations
- 🇩🇪
Technical University Munich, Munich, Germany
Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03242499
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Neurophysiological and Acute Pharmacological Studies in FXS Patients
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 29
- Registration Number
- NCT02998151
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Interventions for Reading Disabilities in NF1
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 120
- Registration Number
- NCT02964884
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome
- Conditions
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 30
- Registration Number
- NCT02642653
- Locations
- 🇺🇸
UC Davis MIND Institute, Sacramento, California, United States
Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02603770
- Locations
- 🇺🇸
NRC Research Institute, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.